ADDvise receives order worth EUR 2.1 million
ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly. The order is worth approximately EUR 2.1 million and involves advanced laboratory instruments for quality control purposes. The instruments will be used in a new manufacturing facility for biologic pharmaceuticals in Limerick, Ireland. Delivery of the order is scheduled to the fourth quarter 2024. For further information, please contact: Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information This information is information that